BACKGROUND: The quality of oral anticoagulant therapy may be related to which type of coumarin is used. The aim was to investigate whether phenprocoumon or warfarin provide the highest quality of oral anticoagulant therapy in patients who manage the therapy themselves. METHODS AND RESULTS: In a cohort study 519 patients on self managed oral anticoagulant therapy were included. Quality control parameters, were, the percentage of time spent in the therapeutic range and the variability in the patients' INR values. Time within therapeutic INR target range in the patient group treated respectively with warfarin and phenprocoumon was 70.2% and 74.0% (P = 0.008).The median variance in the warfarin group was 0.35 (95% CI (0.32-0.38)) and 0.29 (95% CI (0.25-0.33)) in the phenprocoumon group (P = 0.0004). CONCLUSION: Phenprocoumon provides a higher percentage of time spent in therapeutic INR interval and a lower variation of INR-values compared with warfarin.
BACKGROUND: The quality of oral anticoagulant therapy may be related to which type of coumarin is used. The aim was to investigate whether phenprocoumon or warfarin provide the highest quality of oral anticoagulant therapy in patients who manage the therapy themselves. METHODS AND RESULTS: In a cohort study 519 patients on self managed oral anticoagulant therapy were included. Quality control parameters, were, the percentage of time spent in the therapeutic range and the variability in the patients' INR values. Time within therapeutic INR target range in the patient group treated respectively with warfarin and phenprocoumon was 70.2% and 74.0% (P = 0.008).The median variance in the warfarin group was 0.35 (95% CI (0.32-0.38)) and 0.29 (95% CI (0.25-0.33)) in the phenprocoumon group (P = 0.0004). CONCLUSION:Phenprocoumon provides a higher percentage of time spent in therapeutic INR interval and a lower variation of INR-values compared with warfarin.
Authors: A P A Gadisseur; W G M Breukink-Engbers; F J M van der Meer; A M H van den Besselaar; A Sturk; F R Rosendaal Journal: Arch Intern Med Date: 2003-11-24
Authors: A J Azar; J W Deckers; F R Rosendaal; P F van Bergen; F J van der Meer; J J Jonker; E Briët Journal: Thromb Haemost Date: 1994-09 Impact factor: 5.249
Authors: Alain P A Gadisseur; Felix J M van der Meer; Henk J Adriaansen; Stephan D Fihn; Frits R Rosendaal Journal: Br J Haematol Date: 2002-06 Impact factor: 6.998
Authors: Henry Christensen; Jens-Jacob Lauterlein; Patricia D Sørensen; Eva R B Petersen; Jonna S Madsen; Ivan Brandslund Journal: Telemed J E Health Date: 2011-01-23 Impact factor: 3.536
Authors: Tiago L L Leiria; Renato D Lopes; Judson B Williams; Jason N Katz; Renato A K Kalil; John H Alexander Journal: J Thromb Thrombolysis Date: 2011-05 Impact factor: 2.300